Unknown

Dataset Information

0

Plasma metabolomics in EGC patients during PD-L1 based immunotherapy

ABSTRACT: The PUCH Center's cohort of EGC (gastroesophagus cancer) patients undergoing immunotherapy aims to explore the corresponding plasma metabolomic changes associated with alterations in body composition during immunotherapy.

ORGANISM(S): Homo sapiens (human)

SUBMITTER:  

PROVIDER: S-BSST1712 | biostudies-other |

REPOSITORIES: biostudies-other

Json Xml

Similar Datasets

Unknown Plasma metabolomics in EGC patients during PD-L1 based immunotherapy
| S-BSST1713 | biostudies-other
Unknown Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy.
| S-EPMC11464919 | biostudies-literature
Unknown Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors.
| S-EPMC11243122 | biostudies-literature
Unknown Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy.
| S-EPMC11405167 | biostudies-literature
Unknown Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
| S-EPMC6209395 | biostudies-literature
Unknown Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
| S-EPMC7164376 | biostudies-literature
Unknown HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
| S-EPMC9395140 | biostudies-literature
Unknown Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.
| S-EPMC8710491 | biostudies-literature
Proteomics Branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC
2025-05-06 | PXD045506 | Pride
Unknown An update on immunotherapy with PD-1 and PD-L1 blockade.
| S-EPMC8688791 | biostudies-literature